Livforsakringsbolaget Skandia Omsesidigt Has $1.15 Million Position in Danaher Co. (NYSE:DHR)

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in Danaher Co. (NYSE:DHR) by 19.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,954 shares of the conglomerate’s stock after purchasing an additional 822 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Danaher were worth $1,147,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BKM Wealth Management LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $27,000. OFI Invest Asset Management bought a new stake in shares of Danaher in the third quarter valued at about $30,000. First Capital Advisors Group LLC. bought a new stake in shares of Danaher in the second quarter valued at about $32,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Danaher in the third quarter valued at about $34,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Danaher in the fourth quarter valued at about $36,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 1.7 %

Shares of NYSE DHR opened at $235.27 on Thursday. The company’s fifty day moving average is $249.28 and its 200-day moving average is $229.86. The stock has a market cap of $174.23 billion, a price-to-earnings ratio of 37.46, a P/E/G ratio of 3.65 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.87 earnings per share. Equities research analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 16.90%.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Barclays increased their target price on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. Royal Bank of Canada raised their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Citigroup raised their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, KeyCorp raised their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.